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Abstract 
Understanding historical trends in the epidemic of HIV is important for assessing current and projecting future trends in 
prevalence, incidence and mortality and for evaluating the impact and cost-effectiveness of control measures. In generalized 
epidemics the available data are of variable quality among countries and limited mainly to trends in the prevalence of HIV 
among women attending ante-natal clinics. In concentrated epidemics one needs, at the very least, time trends in the prevalence 
of HIV among different risk groups, including intravenous drug users, men-who-have-sex-with-men, and commercial sex 
workers as well as the size of each group and the degree of overlap between them. Here we focus on the comparatively straight 
forward problems presented by generalized epidemics. We fit data from Kenya to a susceptible-infected model and then 
successively add structure to the model, drawing on our knowledge of the natural history of HIV, to explore the effect that 
different structural aspects of the model have on the fits and the projections.  
 Both heterogeneity in risk and changes in behaviour over time are important but easily confounded. Using a Weibull 
rather than exponential survival function for people infected with HIV, in the absence of treatment, makes a significant 
difference to the estimated trends in incidence and mortality and to the projected trends. Allowing for population growth has a 
small effect on the fits and the projections but is easy to include. Including details of the demography adds substantially to the 
complexity of the model, increases the run time by several orders of magnitude, but changes the fits and projections only 
slightly and to an extent that is less than the uncertainty inherent in the data. We make specific recommendations for the kind 
of model that would be suitable for understanding and managing HIV epidemics in east and southern Africa. 
  
Introduction 
There are three rules of good modelling in epidemiology. 
First: stay as close to the data as possible. Second: include 
as much biology as possible. Third: keep it simple. Einstein 
expressed this more elegantly in observing that ‘… the 
supreme goal of all theory is to make the irreducible basic 
elements as simple and as few as possible without having to 
surrender the adequate representation of a single datum of 
experience’.1 
 Here we use HIV-prevalence data from ante-natal 
clinics (ANCs) in Kenya where the time trends and the 
quality of the data are typical of many African countries. 
We first fit a susceptible-infected (SI) model and explore 
ways of dealing with heterogeneity in the risk of infection 
and changes in overall risk behaviour. We then allow for 
the known Weibull survival distribution for people infected 
with HIV and for population growth. Finally we include 
details of the demography including the age dependent 
background mortality, the age-specific mortality for those 
infected with HIV but not on anti-retroviral therapy (ART), 
and the age-specific incidence of infection. We do not 
separate people out by sex and we do not include details of 
the age-matching of sexual partners. 
Data 
While the ANC data for Kenya are of variable coverage and 
quality and the size of the epidemic differs significantly 
among countries in Africa, the data for Kenya are sufficient 
to establish a reasonable estimate of the national trend2 and 
are representative of the trends seen in other countries in 
Africa.  
 For the compartmental models we only use data on the 
estimated time-trends in the prevalence of HIV infection in 
adults and the coverage of anti-retroviral therapy (ART). 
Because the prevalence data are from estimates of the 
underlying trend, fitted to smooth functions, we have added 
normally distributed random numbers to the estimates with 
standard deviations estimated from the published 
uncertainty bounds to simulate the actual data. 
 For the demographic model we need considerably more 
data. To determine the age-specific background mortality 
we use the current age-distribution of people in Kenya, the 
current population growth rate, and we assume a stable age 
distribution.3 We use data on the age-specific incidence of 
infection from a study in South Africa4 and data from the 
Cascade study5 to estimate the survival of people as a 
function of the age at which they were infected.6 
Results 
We first fit a basic SI model to the prevalence data from 
Kenya. To this we add additional structure to allow for 
heterogeneity in risk behaviour and for changes in 
behaviour over time. We then replace the implied 
exponential survival with a Weibull survival and then allow 
the population to grow over time. Finally introduce details 
of the demography. 
 
 
 
 
Figure 1. People are infected at a per 
capita rate β I, uninfected (susceptible) 
people die at a per capita rate δ and 
infected people die at a per capita rate μ. If 
we feed δ S back into S we can omit it and 
if we let S + I = 1, we are working with 
proportions. 
β SI 
S I 
μI 
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SI model 
The SI model is shown in Figure 1.  Assuming that AIDS 
related mortality, μ, is 0.1/year corresponding to a mean 
life expectancy of 10 years without treatment, the model 
has two parameters: the prevalence of HIV in 1970, when 
the model is started, and the transmission parameter, β, 
which determines the initial rate of increase. Fitting the SI 
model to the trend in the prevalence of HIV in Kenya gives 
the fit shown in Figure 2. As expected the model can fit the 
initial rise but not the peak and subsequent decline. 
Although the SI model only fits the early rise in infection it 
provides an estimate of 0.47/year for the initial growth rate 
and hence an estimate of 4.7 for R0 = β/μ.7 
 
 
 
 
 
 
 
 
 
Figure 2. The SI model (Figure 1) fitted to the prevalence of 
HIV in Kenya.2 The model is fitted to the data up to 1992. 
Blue: data with confidence limits; Green: prevalence; Red: 
annual incidence; Brown: annual mortality. 
Heterogeneity in risk 
In order to fit the peak prevalence of HIV we need to allow 
for heterogeneity in the risk of infection among people.8 
Given that high risk people are likely to be infected before 
low risk people, we assume that the transmission parameter, 
β, declines as the prevalence increases9 and the rate at 
which this happens is varied to fit the data. If the functional 
form of this relationship is 
 ( )* e
nPαβ β −=  1 
then with n = 1 transmission declines exponentially with 
prevalence and as n → ∞ the relationship approaches a step 
function. If we assume, instead, that a proportion P* = 1/α  
are at risk while the rest are at no risk we have  
 ( )* 1 Pβ β α= −  2 
(and β * = 0 if α P > 1) so that β * declines linearly from  β 
when P = 0 to 0 when P = 1/α. Replacing β by β * in 
Figure 1 the model has two variable parameters: β and α.  
 Figure 3 shows the best fit to the data up to 1995 with n 
= 1, 2 and 4 using Equation 1 and using Equation 2. In all 
cases the prevalence curve lies precisely under the mortality 
curve because we are assuming exponential survival, and 
therefore a constant hazard of death, so that with an annual 
mortality rate of 10% for those infected with HIV the 
mortality is always 10% of the prevalence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The SI model (Figure 1), allowing for heterogeneity in the risk of infection, fitted to the 
prevalence of HIV. A: n = 1; B: n = 2; C: n = 4 (Equation 1) and D: linear decline (Equation 2). Blue: data 
with confidence limits; Red: annual incidence; Brown: annual mortality. The prevalence curve (primary 
axis) lies exactly beneath the brown mortality curve (secondary axis); see text for details. 
 All four models (Equations 1 and 2) give equally good 
fits to the data up to 1995 so that the prevalence data alone 
are insufficient to decide among them. However, there are 
significant differences in the implied incidence curves and 
in the asymptotic prevalence. The peak value of the 
incidence increases from 2.1% p.a. when n = 1 (Figure 3A) 
to 2.4 % p.a. when n = 4 (Figure 3C) and the peak of the 
incidence cure is much flatter when n = 1 and much sharper 
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when n = 4. There are also significant differences in the 
asymptotic prevalence which falls from 16.5% when n = 1 
(Figure 3A) to 11.1% when n = 4 (Figure 3C). Furthermore, 
the estimated values of R0, calculated as β/μ, fall from 6.3 
when n = 1 to 4.6 when n = 4. However, the fitted curves 
for n = 2 (Equation 1; Figure 3A) and for the linear decline 
with prevalence (Equation 2; Figure 3D) are very similar. 
To explain this we plot the reduction in transmission as a 
function of the prevalence in Figure 4. In all cases the 
asymptotic prevalence is reached when the transmission is 
reduced by a factor of about 5 but the long tail on the 
exponential curve (n = 1; Figure 4, blue line) gives a 
significantly higher asymptotic prevalence than the short 
tail on the Gaussian curve (n = 2; Figure 4, red line ) but the 
latter is close to the asymptotic prevalence assuming that 
transmission declines linearly with prevalence (Figure 4, 
green line). In the models that follow we shall use Equation 
1 with n = 2 to allow for heterogeneity in the risk of 
infection but note that the functional form of this 
relationship makes a significant difference and an 
epidemiological basis for choosing this function would 
significantly improve our confidence in the results. 
 
 
 
 
 
 
 
Figure 4. Transmission as a function of prevalence. 
Blue: n = 1; Red: n = 2; Brown: n = 3; Green: 
Linear. (See Equations 1 and 2). Dots indicate the 
reduction in transmission at the asymptotic 
prevalence. 
Control 
It is clear from Figure 3 that as the mortality rises the 
incidence, but not the prevalence, falls and there must have 
been a decline in the force of infection, after about 1995, 
which is not attributable to the natural history as captured 
by the model even allowing for heterogeneity in infection 
and, of course, mortality. This decline in risk over time 
could result from changes in people’s behaviour as they 
become more aware of HIV or from changes bought about 
by external interventions resulting in increased condom use, 
delayed age of sexual debut, having fewer partners, changes 
in peoples movement and so on. 
 Whatever the reason for the decline in prevalence after 
1997 we can add an external ‘control’ by letting the force 
of infection decline over time in a logistic fashion so that 
we replace β * in Figure 1 by β † where 
 
( )† *
( )(1 )
e( ) ( )
1 e
c c
c c
c c
t
t
t t
ρ
ρ
τα τ αβ β
−
−−
⎡ ⎤= +⎢ ⎥+⎢ ⎥⎣ ⎦
   3 
The term in square-brackets falls from 1 before the 
epidemic starts, converges to an asymptote αc, at a rate ρc, 
reaching half the asymptotic value at time τc.  
 We do not specify the reason for this decline in the 
force of infection but the model will tell us by how much 
the force of infection must have changed to fit the data and 
the challenge is to find an explanation for a change of this 
magnitude. The model now has six variable parameters; 
μ and β (Figure 1), α (Equations 1 or 2) plus αc, ρc and τc  
(Equation 3). Fitting this model to the trend in the 
prevalence of HIV gives the result shown in Figure 5.  
 
 
 
 
 
 
 
 
 
Figure 5 . The model in Figure 1 allowing for heterogeneity in 
the risk of infection and for reductions in the risk of infection 
over time, fitted to the prevalence data. The prevalence curve 
(primary axis) lies exactly beneath the brown mortality curve 
(secondary axis); see text for details. 
 The fit to the data implies that the risk of infection fell 
by 85% in the four years between about 1991 and 2002 but 
has remained constant since then as shown in Figure 6. 
 
 
 
 
 
 
 
Figure 6. The decline in the risk of 
infection implied by the decrease in the 
prevalence of infection in Figure 5 from 
the model including control as defined in 
Equation 3. 
Confounding 
There is now a further problem that must be addressed. 
Heterogeneity in the risk of infection and changes in the 
risk of infection over time can both be used to control the 
peak prevalence in the model even though changes in the 
risk of infection over time although only some level of 
control can lead to a decline in incidence and prevalence. 
To illustrate this we go back to the model in Figure 1 
keeping the control term (Equation 3) but leaving out the 
effect of heterogeneity in risk (Equation 1). This gives the 
fit shown in Figure 7 and the implied reduction in the risk 
of infection over time shown in Figure 8. The fits and 
implied incidence in Figure 5 and Figure 7 are similar but 
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the effect of control shown starts about three years earlier, 
the control takes effect more slowly and the asymptotic risk 
reduction is 90% rather than 85% (compare  Figure 6 and 
Figure 7). 
 
 
 
 
 
 
 
 
 
Figure 7. The model in Figure 1 , allowing for reductions in 
the risk of infection over time but not heterogeneity in the risk 
of infection, fitted to the prevalence data. The prevalence 
curve (primary axis) lies exactly beneath the brown mortality 
curve (secondary axis); see text for details. 
 
 
 
 
 
 
Figure 8. The decline in the force of 
infection implied by the decrease in the 
prevalence of infection in Figure 5 from 
the model including the control implied in 
Equation 3. 
 Both models fit the prevalence data in 2015 (5%) and 
then continue to fall. Allowing for heterogeneity and 
control the prevalence falls to 1.5% in 2050 but if we allow 
for control only the prevalence falls more quickly reaching 
0.8% in 2050 (data not shown). 
 While the data, in themselves, do not allow us to 
decisively separate the effect of heterogeneity in risk and in 
control the long term consequences are significantly 
different and this must be considered when making forward 
projections. 
 These data remind us that, with this model, the initial 
rate of increase in the incidence is β − μ so that β ≈ 0.5/year 
and μ ≈ 0.1/year the initial rate of increase in the prevalence 
of infection is about 0.4/year and the prevalence will double 
every ln(2)/0.4 = 1.7 years. Even if transmission were 
stopped entirely the prevalence would fall at about 0.1 per 
year so that the incidence would halve every ln(2)/0.1 years 
= 7 years. If we were to assume a value of R0 = 5 and 
interventions that reduced transmission by 90% it would 
take about 90 years to reduce the prevalence by a factor of 
100. 
Weibull survival 
Survival after infection with HIV is not exponential, which 
would imply a constant hazard, but rather follows a Weibull 
distribution with a shape parameter a little greater than 2 
implying that mortality increases more or less linearly with 
time since infection. Detailed data on the survival with 
HIV, but without ART, as a function of the age at infection 
are available from the CASCADE cohort.5 Fitting these 
data to Weibull survival functions for the probability of 
surviving for t years after being infected 
 ( / )( | , ) 2 tW t
σμμ σ −=  4 
gives the median survival, μ, and shape parameter, σ , as 
 16.492  0.172aμ = −  5 
 2.673  0.011aσ = −  6 
where a is the age at infection in years.6 In most 
generalized epidemics the incidence of infection peaks 
between the ages of about 25 and 30 years, earlier in 
women than in men. For a Weibull distribution the mean 
survival m is  
 ( ) 1/11 ln(2)m σσμ= Γ +  7 
so that for those infected at 25 years of age the mean 
survival is 10.6 years while for those infected at 30 years of 
age it is 9.8 years. For the purposes of this study we assume 
a mean survival of 10 years and a shape parameter σ of 2.3. 
The survival curve for this distribution is close to a Γ-
distribution, with a mean survival of 10 years and a shape 
parameter of close to 4. This in turn means that a good 
approximation to the survival distribution is obtained by 
using four compartments for those infected with HIV and a 
median duration in each compartment of 2.5 years or a rate 
of progression from one compartment to the next of 1/2.5 
or 0.4 per year as shown in Figure 9. 
 
 
 
Figure 9. SI model with the addition of four stages 
of HIV infection to allow for the survival 
distribution of people infected with HIV. 
  The model in Figure 9 gives the fit to the data shown in 
Figure 10. The peak incidence is a little lower at about 
1.8% p.a. (Figure 10) compared to 2.2% p.a. (Figure 5). 
The current (2015) incidence is higher at 0.31% p.a. 
(Figure 10) compared to 0.23% p.a. (Figure 5).* 
 Figure 11 shows the implied reduction in the force of 
infection using the model in Figure 9 and the fit in Figure 
10. The reduction in the force of infection is now 85% close 
to the value of 83% implied by the model in Figure 5 
although it starts about two years earlier. 
 The most important change resulting from the inclusion 
of four stages of HIV-infection (Figure 9) is that it 
introduces a delay of about 10 years between the rise and 
fall of the incidence curve and the rise and fall of the 
mortality curve as is immediately clear by comparing 
Figure 5 and Figure 10. This is important if we wish to 
                                                          
*  The peak prevalence, by definition corresponds to the point at which 
mortality exceeds incidence (see Figure 5, Figure 7 and Figure 10). 
While prevalence peaks when mortality exceeds incidence this only 
implies convergence to a lower asymptote, it does not imply elimination. 
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model the initial trends, the impact of interventions, and 
future projections accurately. 
 
 
 
 
 
 
 
 
 
Figure 10. The model in Figure 9 fitted to the prevalence data 
including four stages of HIV infection to allow for the Weibull 
survival distribution for people infected with HIV. 
 
 
 
 
 
 
Figure 11. The decline in transmission 
implied by the decrease in the prevalence 
of infection in Figure 10 from the model 
in Figure 9. 
Population growth 
So far all the models have expressed the data in terms of the 
number of people in each state as a proportion of the total 
population. In practice the total population is increasing in 
most countries badly affected by the epidemic of HIV and 
we need to know how this affects the model fits and 
predictions. We therefore extend the model in Figure 9 to 
allow the population to grow by separating the background 
mortality, the HIV progression and AIDS deaths, and the 
birth rate, as shown in Figure 12. 
 
 
 
Figure 12. The model shown in Figure 9 but separating births 
(β), background mortality (δ) and HIV progression and death 
(ρ). 
 We now use the model shown in Figure 12, set the 
crude birth rate to 3.6% per year and the background 
mortality to 1.2% per year so that the population grows at a 
rate of 2.4% per year in the absence of HIV. The gives the 
fit shown in Figure 13. 
 Allowing the population to grow introduces further 
changes. Comparing Figure 13 with Figure 10 we see that 
allowing for population growth increases the incidence, as a 
proportion of the total population, by about 10% and 
decreases the mortality, as a proportion of the total 
population by about 10% because the incidence rises when 
the population is smaller and the mortality rises when the 
population is greater.† 
 
 
 
 
 
 
 
 
 
Figure 13. The model in Figure 12 making allowance for the 
growth of the population and plotting the rates as a proportion of 
the total population at a given time. Blue: data with confidence 
limits; Green: fitted prevalence. Red: annual incidence; Brown: 
annual mortality. 
Treatment 
To assess the impact of treatment we need to consider the 
mortality of people on ART.  With modern, triple-therapy 
the survival of people on ART, is close to the survival of 
HIV-negative people even for those that start late in the 
course of their HIV infection.10 In 30 year old adults in 
Kenya the mortality rate, in the absence of HIV, is about 
1.2% per year.3 In a study with a mean duration of follow 
up of about 3 years based on data from Uganda, Malawi 
and Kenya,11 the annual AIDS related mortality in people 
infected with HIV was 0.4%. 0.6%, 0.9%, 1.9% and 7.4% 
in those starting ART at CD4+ cell counts > 500, 350–500, 
200–350, 50–200 cells/μL. Only in the two lowest CD4+ 
cell count categories is mortality higher than the average 
mortality in HIV-negative people. For the model including 
treatment we will assume that those on ART experience the 
same mortality as those not on ART. 
 
 
 
 
 
Figure 14. The model shown in Figure 12 but allowing people 
to start ART at different rates in each HIV-compartment and 
assuming that survival on ART is the same as in HIV-
negative people. 
 In order to fit the data to the model in Figure 14 we vary 
the previous six parameters needed for the model without 
ART: the prevalence of HIV at the start of the epidemic, 
two parameters defined in Equation 1 and the three 
parameters defined in Equation 3. We also let the coverage 
of ART increase logistically so that the proportion of the 
whole population that is on ART is given by  
                                                          
†  Note that an effect of population growth is that the peak prevalence now 
occurs 2.5 years before the mortality exceeds the incidence (see Figure 
13).  
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where the coverage converges to an asymptote of αa, at a 
rate ρa reaching half the asymptotic value at time τa. We 
also have to decide on the coverage in each stage of 
infection. Ideally one would use field data to inform these 
numbers but for the present purposes we first assume an 
overall coverage rate of 90% but only for people in Stage 4 
as indicated in Figure 14 so that α4 = 0.90. This gives a 
reasonable but not quite adequate fit so we allow for 
coverage of people in Stage 3. This gives a good fit with α3 = 0.63 as shown in Figure 15.  
 Allowing for the reported coverage of ART we see that 
with about half of all HIV-positive people in Kenya on 
ART, the incidence has fallen by about 50% and the 
mortality by about 90%. One could, of course, achieve an 
equally good fit to the coverage data by assuming that more 
people are started in Stages 1 and 2 and fewer people in 
Stages 3 and 4; the important point is that the model allows 
us to explore the impact of starting ART earlier or later. 
 
 
 
 
 
 
 
 
 
 
Figure 15. The model in Figure 14, allowing for the increasing 
coverage of ART but assuming that most of people start ART 
in Stage 4 and some in Stage 3. Blue: data with confidence 
limits; Green: fitted prevalence. Red: annual incidence; 
Brown: annual mortality; Pink: ART coverage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. The fits in Figure 15 with 95% confidence bands on the fitted curves. A: All fitted curves; B: Annual incidence; C: 
Total prevalence, blue: Prevalence not on ART, green; D. Annual AIDS related mortality. 
Uncertainty 
Because the compartmental model is still relatively simple 
we can easily calculate uncertainties in the fitted parameters 
and fitted curves using a Markov-Chain Monte Carlo 
algorithm with a Gibbs sampler and binomial errors. This 
gives the results show in Figure 16. Even with relatively 
good data on the trends in the prevalence of HIV there is 
considerable uncertainty in the projected values. In 2030 
the projected annual incidence is 0.30% (0.17% to 0.56%), 
the prevalence among those not ART, assuming that the 
coverage of ART remains at about its present level, is 1.8% 
(1.1% to 3.2%) and the annual mortality is 0.02% to 
0.05%). 
 
Demography 
A full demographic model adds considerable complexity 
and it is important to investigate the extent to which this 
changes the fits and projections of the model. We need to 
allow for: 
1. The age-specific mortality in people who are not 
infected with HIV, which may change over time. 
2. The birth rate which may change over time and 
depends on the number of women of reproductive age. 
3. The age-specific risk of infection. 
4. The age-specific survival of people on ART. 
5. The age distribution of people’s sexual partners. 
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6. The difference in the risk of infection in men and in 
women. 
 Dealing precisely with the age-mixing of sexual 
partners is complicated and we will ignore this aspect of the 
demography for the present work. This gives the model 
illustrated in Figure 17. 
 
 
 
  
 
 
 
 
 
Figure 17. Overview of the demographic model. Green arrows: 
births and ageing of uninfected people; Pink arrows: incident 
infections; Red arrows: progression of people infected with HIV; 
Purple arrows: people starting ART; Brown arrows: people failing 
ART; Black vertical arrows: background mortality; Red vertical 
arrows: AIDS related mortality; Blue vertical arrows: mortality on 
ART. Each column of points represents people whose age is one 
time step greater than the previous column of points. 
 For the model in Figure 17 we need to use a time step of 
0.1 year because the important rate processes are of the 
order of 1/year and models without demography show that 
this time step is sufficiently small to ensure stability of the 
solutions. We also use an age interval of 0.1 year. If we 
consider people of ages 0 to 100 years then the model in 
Figure 16 has 106 states and that need to be updated from 
say 1970 to 2030 or 60 years and 600 time intervals. The 
number of states that need to be calculated over the course 
of one simulation is therefore of the order of 6×108. This 
then has to be repeated a sufficient number of times to 
ensure that the variable parameters provide the best fit to 
the observed data. A fuller discussion of the computational 
details of the demographic model is given in Appendix 1. 
Age-dependent mortality  
The age distribution will change over time but we assume 
here that the current age distribution is stable. We therefore 
take the current age distribution and the overall population 
growth rate, r, to estimate the age dependent mortality, 
m(a), 
 ( )11ln( ) aam a r+−= − −  9 
as shown in Figure 18. 
 Using Equation 9 implies negative mortality rates in 
those under the age of 15 years but this is a reflection of the 
fact that fertility has fallen over the last fifty years and the 
age-distribution is changing over time. Here we set the 
mortality to zero below the age of 15 years and then fit the 
mortality above the age of 15 years to an exponential so 
that the fitted mortality ( )m a′  
 ( )( )( ) 1 e am a β γα − −′ = −  10 
where the asymptotic value α = 0.047/year, the rate of 
increase β = −0.025/year and the offset γ is 14.7 years. 
Using Equation 10 and the population growth rate we back-
calculate the stable age-distribution as a check and compare 
it to the current age-distribution (Figure 19) showing that 
the assumed and modelled age distributions are similar. 
 
 
 
 
 
 
 
 
 
 
Figure 18. Age-specific mortality. Red dots: calculated using 
Equation 9; Blue line: fitted to data for those above the age of 15 
years. 
 
 
 
 
 
 
 
 
Figure 19. Red dots: current age distribution. Blue line: assumed 
stable age distribution. 
 As a further check we calculate the probability of 
surviving to any given age (Figure 20) from the full 
demographic model but without HIV. Because we have 
assumed that there is no mortality before the age of 15 
years the curve is flat up to that age. Here we are interested 
in HIV in adults and this assumption will not affect the 
results significantly. 
 
 
 
 
 
 
 
 
Figure 20. Probability of surviving to any given age in the absence 
of HIV. 
 As a final check we calculate the survival distribution of 
a person aged 30 years (Figure 21) and this agrees with the 
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assumed survival based on the Cascade data5 (Equations 5 
and 6) 
 
 
 
 
 
 
 
 
Figure 21. Calculated survival for those infected with HIV at 30 
years of age. 
 The assumed age-specific incidence of infection (Figure 
22)4 implies that people become sexually active at the age 
of about 15 years, the risk of infection peaks at the age of 
about 32 years and falls to 10% of the peak value at the age 
of 60 years. 
 
 
 
 
 
 
 
 
Figure 22. Assumed age-specific incidence of infection 
normalized to 1. 
 As a final check we run the model without HIV to 
confirm that it gives the right rate of growth of the 
population (Figure 23). The slope of the curve (2.4% p.a.) 
is equal to the assumed crude birth rate (3.6% p.a.) minus 
the assumed crude mortality rate (1.2% p.a.) 
 
 
 
 
 
 
 
 
Figure 23. The growth of the population in the absence of HIV 
calculated from the demographic model. The slope of the curve is 
2.4% per year.  
 We then use the demographic model to get the best fit to 
the prevalence data without ART. As before, we vary the 
six key parameters: the prevalence in 1970, the force of 
infection, and the heterogeneity, as well as the three 
parameters that define the fall in the force of infection over 
time (Equation 3). The fitted and implied trends for the best 
fit model are given in Figure 24. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. The best fit of the full demographic model, without 
ART. 
 The full demographic model gives a peak incidence of 
1.9% p.a., close to the value of 2.0% p.a. in the 
compartmental model, and about the same incidence of 
0.4% in 2015. The full demographic model gives a peak 
mortality of about 0.8% p.a. compared to about 0.9%, and a 
current value of the mortality of 0.4% as compared to 0.5%. 
We can also compare the implied reduction in transmission 
over time for the compartmental model and the full 
demographic model. The compartmental model implies the 
transmission must have fallen by about 80% while the full 
demographic model implies that it fell by 74%. 
 
 
 
 
 
 
 
 
 
Figure 25. The implied decline in transmission for the full 
demographic model. 
Discussion 
In this paper we start from the basic SI model and then add 
structure step-by-step. We are interested in knowing what 
effect different structural additions have, how important 
they are, which need to be included and to what extent they 
add to our understanding of the underlying biology.  
 The basic SI model describes the initial exponential rise 
in the prevalence but cannot fit the peak prevalence. It is 
therefore essential to allow for a decline in the average risk 
of infection as prevalence increases. The difficulty here is 
that a wide range of risk functions from an exponential to a 
step-function dependence on prevalence give equally good 
fits to the prevalence data but imply significantly different 
incidence and mortality rates. If data were available on the 
incidence or mortality it would help to resolve this problem 
but resolve it we must. 
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 In some countries such as Kenya, illustrated here, and 
Zimbabwe12 prevalence has fallen substantially and quite 
rapidly from a peak while in others, such as South Africa, 
the prevalence shows no sign of declining.13 Where such a 
decline has been observed the reasons for the decline are 
unclear. It could be that people have changed their 
behaviour, and have sustained this change over time, as a 
result of a general awareness of the epidemic. It could be 
that people have changed their behaviour as a direct 
response to AIDS related deaths but an analysis of data 
from Zimbabwe suggests that this is not the case. Finally, it 
could be a result of the intrinsic dynamics of the 
transmission network but there are no convincing models 
that support this. We therefore allow for a logistic reduction 
in the transmission parameter. This allows us to fit the data 
and gives a measure of the extent to which transmission 
must have fallen. While it does not provide the answer to 
the question is defines the question more precisely. 
 The basic model, with only one compartment for 
infected people, implies exponential survival for those on 
ART which we know not to be the case. However, if one 
includes four stages of infection it is then possible to get a 
fairly accurate representation of the average survival of a 
person after they are infected with HIV. This has a 
significant effect on the implied incidence and introduces a 
delay of about 5 years between the rise and fall in the 
prevalence and the rise and fall in the mortality. 
 Allowing the population to grow, rather than working 
with proportions, increases the incidence and decreases the 
mortality, each by about 10%. While this change is small it 
is easily incorporated. 
 Where treatment has been made available the effect of 
this must be included and this of course will have a 
substantial impact on the time course of the epidemic. The 
problem is that few direct data are available on the actual 
coverage of ART in any country in the world. Since, in the 
short term, say five to ten years, the effect of providing 
ART is to leave the total number of people living with HIV 
more or less unchanged while the proportion of people not 
on ART does of course drop, the prevalence data alone are 
not sufficient to confirm the extent to which ART has been 
provided. 
 The full demographic model is much more 
computationally intensive increasing the number of states 
that have to be calculated for each run of the model 
increasing from about 360 in Figure 14 to about 600,000 in 
Figure 17 with a corresponding increase in the time taken to 
run the model and fit it to the data. However the fitted 
prevalence does not change and the implied mortality and 
incidence only change by about 10%. 
Conclusion 
Simple, compartmental models fitted to time trends in the 
prevalence of HIV provide reliable estimates of the 
corresponding time trends in incidence and mortality from 
which projections can be made of the likely impact and cost 
effectiveness of interventions. 
 The models must first allow for heterogeneity in the risk 
of infection among people and second include sufficient 
structure to reflect the survival distribution for people with 
HIV but without ART and dealing with this appropriately 
remains the most important are of uncertainty.8 Allowing 
the population to grow over time makes a small difference 
but does not increase the computational complexity of the 
model. 
 Including details of the demography such as the age-
dependant mortality for those not on ART, age specific 
incidence of infection, and variation of survival on ART as 
a function of the age at infection change the implied 
incidence and mortality only slightly, and probably by less 
than the uncertainty in the data to which the model is fitted,  
but increase the computational burden by four orders of 
magnitude so that it is not worth using a full demographic 
model except in that happy situation where one has detailed 
data on the prevalence of infection as a function of age and, 
better still, reliable data on time trends in the incidence and 
mortality. With a simple compartmental model it is straight 
forward to estimate the uncertainty in the fits using a 
Markov Chain Monte Carlo approach while this would be 
even more demanding of computing power with a full 
demographic model. 
 In summary, simple compartmental models are 
sufficient to model generalized epidemics but a key 
unresolved issue is the nature and effect of heterogeneity in 
sexual behaviour and in sexual mixing patterns. 
Demographic models add substantially to the computational 
burden without changing the fitted and implied 
epidemiological trends significantly. 
Recommendations 
Countries in east and southern Africa, where HIV is mainly 
spread through heterosexual contacts, need to be able to fit 
a suitable model to their data and use this to estimate 
current and predict future trends in the prevalence, 
incidence, mortality and ART coverage while including 
estimates of uncertainty. Based on this study we make the 
following recommendations. 
Use a compartment model 
Including details of the underlying demography changes the 
fits and projections by considerably less than the 
uncertainty that is inherent in the data while increasing the 
run-time for fitting the models from fractions of a second to 
many hours. 
Allow for heterogeneity in risk 
Include a term that allows the risk of infection to fall as the 
prevalence rises. A Gaussian relationship is recommended 
but a biological justification for a different functional form 
would be worth pursuing. 
Allow for changes in risk over time 
In some countries, but not all, it is clear that there has been 
a substantial decline in the risk of infection over time. A 
logistic decline in transmission gives a good fit to the data. 
However, the reasons for this decline or, in some places, for 
the absence of a decline demand further investigation. 
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Allow for the known survival of people not on ART 
A four-compartment model for those infected with HIV 
gives a sufficiently accurate reflection of the average 
survival of those infected with HIV. 
Allow for treatment failure 
Although we have not included it here, allowing for four 
stages for people on ART, so that they move from infected 
stage Ii to ART stage Ai would allow one to vary the 
survival according to the stage of infection when treatment 
was started. If people fail treatment in stage Ii they could 
then be returned to stage Ii. 
Consider including second-line treatment 
This could be included either explicitly, through a further 
set of four compartments, or implicitly by assuming that a 
proportion of people are on second-line treatment. Since 
there is clear evidence that with high coverage and good 
compliance, triple-therapy will eliminate drug resistance 
where it does arise,14 this should be of secondary 
importance. 
Allow for population growth 
Although the effect of population growth is slight it can 
easily be included and is needed if we are to make 
estimates of the number infected and the number of 
incident cases and deaths. 
Allowing for age- and gender-specific rates 
Given the lack of reliable trend data in age-specific rates of 
infection of sexual mixing patterns it should be sufficient to 
distribute the total number of cases according to age and 
gender using measured distributions of prevalence, 
incidence and mortality  
Include ART coverage 
The ART coverage must be included; where possible as a 
function of disease progression. 
Uncertainty bounds 
These must be included as the uncertainty is likely to be 
significant. 
Outputs 
The model outputs should include current and projected 
trends in prevalence, on and off ART, incidence, the rate at 
which people start ART, and mortality, all with 
uncertainties. Including the prevalence off ART for the 
different stages of infection could be useful as the cost of 
treating AIDS related conditions will depend on the stage 
of infection. 
Caveat 
ART has not been included in the full demographic model. 
While this adds further complexity and it might be 
interesting to explore this, it seems that the full 
demographic model is not generally needed and we have 
not pursued this further here. 
Appendix 1. Computational details of the 
demographic model 
An overview of the demographic model is given in Figure 
17. The detailed assumptions are as follows. 
Demography without HIV 
The age-specific death rate determines the mortality at each 
black arrow and these background mortalities, Βi at age i, 
also apply to the infected stages. These and the birth rate, β, 
remain fixed. 
Age specific incidence 
An estimate of the relative age-specific incidence is used to 
determine the age-specific transmission paramter Fi, which 
we multiply by a factor λ which will be varied to optimise 
the objective function. 
Age specific mortality with HIV 
The age-specific, AIDS-related mortality, jiA , which 
depends on the age at infection i and the current age j so 
that the time since infection is j − i. This is chosen so that 
survival after infection follows a Weibull distribution as a 
function of the age at infection and the time since infection 
with the parameter values given in Equations 5 and 6. 
Age specific mortality on ART 
We let this be the same as the mortality in HIV-negative 
people. 
Rate of starting ART 
We start by keeping the rate of starting ART fixed but we 
could let it vary with age and/or with the time since 
infection and set it to jiT . We have a separate parameter, σ, 
that scales the rate at which ART is rolled out so that we 
can decide when to introduce ART and to what coverage. 
Rate of failing ART 
We start by keeping the rate of failing (stopping) ART 
fixed but we let it vary with age and with the time since 
infection and we set it to jiS . We have a separate 
parameter, φ, that scales the failure rate but have not 
explored this here. 
Coded structure 
We assume that people can live for up to 100 years. With a 
time step of dt we will need a 100/dt×100/dt population 
matrix and we will let the successive diagonal elements 
correspond to the ages of the uninfected people. ( )ii tN  is 
the number of susceptible people of age idt at time t. 
 The elements above the diagonal correspond to people 
who are infected with HIV so that the element ( )ji tN , j > i, 
gives the number of people who were infected with HIV at 
age i and are now of age j at time t. 
 The elements below the diagonal correspond to people 
who are infected with HIV and on ART so that the 
element ( )ji tN , j < i, gives the number of people who were 
infected with HIV at age i and are on ART at age j. 
 Uninfected people may remain uninfected, they may 
die, or the may become infected. Infected people may 
remain infected, they may die, or they may start ART. 
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People on ART may remain on ART, may die or may fail 
treatment. 
Implementation 
To implement the programme we first set up the following 
vectors and matrices where all the elements are 
probabilities per unit time step. 
iB : probability of dying, from causes unrelated to AIDS, 
for a person of age i; 
j
iA : probability of dying from AIDS for a person infected 
at the age i and now of age j. 
iT : probability of starting treatment i years after being 
infected. 
iS : probability of failing (stopping) treatment i years after 
being infected. 
iF : the relative force of infection for a person of age i. 
To initialize the (time-dependant) matrix N(t) we set 
(0)iiN  to the age-distribution of people of age i at time 0, 
normalized to 1. We set the crude birth rate β and then 
choose the values of background mortality Bi so that the 
elements of (0)iiN  match the current age-distribution 
assumed to be the stable age-distribution. 
 
 
 
 
 
 
 
 
 
 
Figure 26. Labelling the states for reference to Equations 11 to 26. 
Heavy arrows are those that survive from one time to the next. 
Green: susceptible; red: infected; blue: treated. Light arrows are 
those that change their state. Black: background mortality; red: 
AIDS mortality; blue: mortality on treatment; pink: incident cases; 
purple: starting treatment; brown; stopping treatment. 
 We then define the following variables as a function of 
time t: 
Number of susceptible people 
  ( )( ) ii
i
S t t= ∑N  11 
Number of people infected with HIV, not on ART, (only 
those older than 15 can be infected) 
  ( )
,
( ) ji
i j i
H t t
>
= ∑ N  12 
Number of people on ART (treatment) (only those older 
than 15 can be infected) 
  ( )
,
( ) ji
i j i
T t t
<
= ∑ N  13 
Total population 
  ( ) () ( )( )N t H ttS t T= + +  14 
Birth rate (children) 
  ( ) ( )C t N tβ=  15 
Adult population 
  ( )
15,
( ) ji
i j
R t t
>
= ∑ N  16 
Adult prevalence of HIV 
  ( ) ( ) ( )P t H Rt t=  17 
Adult prevalence of ART 
  ( ) ( ) ( )Q t T Rt t=  18 
Incidence of HIV 
  ( )( )( ) ii i
i
I Pt t tλ= ∑F N  19 
Background mortality 
  ( )
,
( ) ji
i j
BM t t= ∑N  20 
AIDS mortality 
  ( )
,
( ) j ji i
i j i
AM t t
>
= ∑ A N  21 
Iterating over time 
We first consider progression for those infected with HIV 
on and off ART (Figure 27). 
 
 
 
 
 
 
 
 
 
 
Figure 27. Infected people can die of natural causes (background 
mortality) (B), AIDS (A) or start treatment (T). People on 
treatment can die of natural causes (background mortality) (B) or 
stop treatment (S). Note that the red elements (infected with HIV) 
are stored above the diagonal; the blue elements (on ART) are 
stored below the diagonal. The diagonal elements are all 
susceptible and the elements immediately above the diagonal are 
incident cases. Both are dealt with in the text. 
 We now update the matrix of susceptible, infected 
and treated people. We first move from right to left along 
each pair of rows illustrated in Figure 27. At this stage we 
exclude the diagonal and the elements one above and one 
below the diagonal. If d is the dimension of the matrix, the 
loop is 
Uninfected 
Infected
ART
HIV incidence 
ART incidence 
Failure
Background deaths 
i
iN 1iiN
+ 2i
iN
+
2
i
iN + 3
i
iN +
1
1
i
iN
+
+
2
1
i
iN
+
+
3i
iN
+
3
1
i
iN
+
+
1
3
i
iN
+
+
AIDS deaths 
ART deaths 
Age
1j
i−N ijN
j
iN
1j−B
1j
i
−A
1j i− −S
1j i− −T
1j−B
1j
i
−N i = 0
→1000 − 2 
j = 1000 → i + 2 
i = age at infection 
j = current age 
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For i = 0 to d − 2 Step 1 
 For j = d to i + 2 Step −1 
 
  22 
 
  23 
 
 Next 
Next 
 This accounts for all transitions among people infected 
with HIV. We now have to deal with the incident 
infections.  
 
 
 
 
 
 
 
Figure 28. We have to allow for incident infections (pink arrow) 
and the aging of the susceptible population (green arrows) 
 We now update the incident cases:  
  For i = 1 to d − 1 Step 1 
 ( ) ( )1 1 ( ) iiiii tt P tλ+ =+ F NN  24 
  Next 
and then update the susceptible cases: 
 For i = 1 to d − 1 Step 1 
 ( ) ( )( )11 11( )1 1i i ii ii iP tt t λ−− −−+ −= − BFN N  25 
 Next 
and finally account for births:  
 ( ) ( )00 1t T tβ+ =N  26 
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